Back to News
Market Impact: 0.1
Addex's Rocher Returns As Head Of Pharmaceutical Development; Kalinichev Departs For Neurosterix
Source: Nasdaq
Healthcare & BiotechManagement & Governance
Addex Therapeutics appointed Jean-Phillippe Rocher as Head of Pharmaceutical Development and added him to its Executive Management team. The announcement is a routine leadership update for the clinical-stage biopharmaceutical company, with no financial metrics, clinical-data update, or guidance change disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
ADXN0.20
More News
- Mark Ruffalo says Paramount’s $111 billion Warner Bros. deal ‘Will stifle creativity, weaken free speech, and cost people their jobs’
- David Ellison says combined Paramount and Warner Bros. Discovery will be named Skydance
- Paramount’s Warner Bros. megamerger will just be called Skydance
- David Ellison goes minimalist with his new name for his Paramount-Skydance-Warner-Bros-Discovery empire
- Your health insurance premiums may take a big jump in 2027 — here's why
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals